Restricted: To Adult Oncology Infusion Center

Criteria for use:

• Oncologist and facility compliant with REMS program (see pgs 9-11 in dossier for more details).
  • Prescriber: Counsel patient of risk of ocular toxicity and requirement for monitoring via ophthalmic exams (baseline, prior to each dose, and promptly for worsening symptoms); Complete/submit patient enrollment form; assess patient’s ocular health by consulting and eye care professional; Assess the patient’s ophthalmic consult results for appropriateness of initiating treatment.
  • Healthcare setting: train all relevant staff involved in dispensing and administering BLENREP using the program overview, education program for healthcare settings; establish processes and procedures to verify REMS checklist; obtain authorization to dispense each dose; capture dose and date of infusion in online REMS checklist and submit within 5 business days of infusion.
  • Tried and failed at least 3 other multiple myeloma medications including, immunomodulatory, proteasome inhibitor, and an anti-CD38 monoclonal antibody.

• UpToDate
• Lexicomp
• DailyMed Package Inserts
• Johns Hopkins Guides